Galantamine commonly causes nausea, vomiting, dizziness, diarrhea, appetite loss, and weight loss. Caregivers should also watch for fainting, a slow heartbeat, bleeding, or any new rash. Galantamine is a medicine for mild-to-moderate dementia of the Alzheimer's type. It may help manage symptoms, but it does not change the underlying dementing process.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which side effects are most common?
- When are problems most likely?
- Which warning signs need prompt attention?
- What should caregivers tell the care team?
- How should caregivers weigh side effects against benefit?
Which side effects are most common?
Digestive problems deserve the closest day-to-day attention. In pooled trials, nausea affected 20.7% of patients taking galantamine, compared with 5.5% taking placebo. Vomiting occurred in 10.5% versus 2.3%.
Diarrhea, reduced appetite, dizziness, and weight loss were also more frequent. The DailyMed prescribing information reports rates of 7.4%, 7.4%, 7.5%, and 4.7%, respectively. Caregivers can track meals, fluids, vomiting, bowel changes, dizziness, and weight. Report symptoms that persist, interfere with eating or drinking, or make walking unsafe.
When are problems most likely?
Side effects commonly appear when treatment begins or the dose increases. Nausea lasted a median of five to seven days in trials, although an individual patient's experience may differ. The label recommends taking galantamine with meals, maintaining adequate fluids, and waiting at least four weeks before each increase.
These measures may make dose escalation easier to tolerate. Do not dismiss symptoms simply because they began after an increase. Across eight controlled studies, 10.6% of galantamine-treated patients stopped because of an adverse reaction, versus 2.2% taking placebo. Nausea and vomiting were the leading reasons.
Which warning signs need prompt attention?
Galantamine can slow the heart and cause heart block, even without known conduction disease. Fainting became more frequent as doses rose, reaching 2.2% at 12 mg twice daily versus 0.7% with placebo, according to DailyMed's safety warning. Promptly contact the clinician about: Galantamine can increase stomach acid.
Bleeding requires particular vigilance in someone with an ulcer history or who takes a nonsteroidal anti-inflammatory drug, commonly called an NSAID. Serious skin reactions, including Stevens–Johnson syndrome, have also been reported. The label says to discontinue galantamine at the first rash unless the rash is clearly unrelated. If a serious reaction is suspected, the medicine should not be restarted.
- Fainting or an unusually slow heartbeat
- Black or tarry stools
- Red blood in the stool
- Bloody vomit or vomit resembling coffee grounds
- Any new rash
What should caregivers tell the care team?
Give the prescriber and pharmacist a complete medication list. Galantamine can work against anticholinergic medicines, add to the effects of cholinergic drugs, and intensify certain muscle-blocking effects during anesthesia.
Before treatment or a dose change, flag: This review matters even when a condition seems unrelated to memory. Galantamine may worsen respiratory effects, contribute to seizures or bladder obstruction, and affect anesthesia management.
- Severe asthma or chronic obstructive pulmonary disease
- A seizure history
- Difficulty urinating or other possible obstruction symptoms
- A history of ulcers
- Current NSAID use
How should caregivers weigh side effects against benefit?
Galantamine is indicated only for mild-to-moderate dementia of the Alzheimer's type. It is not a treatment for the underlying disease, so continued use depends on whether its symptom benefit justifies its risks and daily burden. A mortality finding from two two-year studies needs careful context.
Those studies involved mild cognitive impairment, not diagnosed Alzheimer dementia: 13 of 1,026 galantamine recipients died, compared with one of 1,022 placebo recipients. The DailyMed label calls that result discrepant with other trials. It is therefore a limitation to discuss with the prescriber, not proof that galantamine caused the deaths.
